Medicare AdvantageCoverageMedium impact
MA08.132e, Margetuximab-cmkb (Margenza)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.132e for Margetuximab-cmkb (Margenza), an oncology drug, has been updated. This is a very recent pharmacy policy change that may affect coverage or prior authorization requirements for this specialty cancer medication.
Action Required
Immediately: Review the full policy MA08.132e on the IBX website to understand specific changes to Margetuximab-cmkb (Margenza) coverage requirements. Oncology billing team should verify current prior authorization and coverage criteria for this medication and update billing procedures accordingly.